Interestingly, the expressions of common oncogenic drivers or inhibitors such as RAS, c-MYC, NOTCH and TP53 are rhythmically controlled by the circadian clock, and also interact with it, thus supporting an overarching regulatory role of the circadian clock in cancer processes and precision cancer treatments. The gene discussed is TP53; the disease is cancer.